Israel Decriminalizes Adult Use Cannabis in Another Step Toward Legalization
April 15th, 2019
Exclusive, News, Top Story
Israel decriminalized adult use cannabis on April 1 — just days before the Jewish state’s April 9 election. The new law makes it legal for Israeli citizens to possess homegrown marijuana plants, while carrying small amounts of cannabis in public will only result in a fine rather than an arrest. The move follows similar legislation across roughly 25 other countries that have legalized cannabis to some extent — ranging from decriminalization to full recreational use.
While the country is smaller than North American cannabis markets, it has already been established as a research capital and could become a gateway to European markets. Dr. Raphael Mechoulam is widely known as the Godfather of Cannabis after discovering tetrahydrocannabinol and paving the way for medical cannabis research. Cannabis research was legal in Israel long before other countries liberalized their laws.
Israel’s unique location could also make it a key gateway to European markets. The government recently legalized cannabis exports earlier this year and analysts believe that regulations could be in place later this year. As a home to more than 740 million people, Europe is roughly double the size of the Canadian and U.S. markets, which represent the two largest legal cannabis markets in the world right now.
Investing in Israel’s Cannabis Industry
ISRACANN Biosciences Inc. [Canadian Listed: IPOT (Pending)] will be Israel’s first pure-play cannabis company to list on a Canadian exchange, with a fully-funded facility of 232,900 sq. ft. With plans to initially target the domestic market before exporting into Europe, investors may want to keep an eye on the stock as it gears up to go public in Canada under the ticker symbol IPOT later this year.
With over 15 years of experience in the capital markets, President and CEO Darryl Jones took True Leaf Medicine public at a $10 million valuation and exited in 2016 with a $150 million market capitalization. He’s joined by an experienced team of cannabis and finance veterans with an established track record of success. The company will also partner with leading Israeli research institutions and universities to leverage their expertise in the market.
The company is well positioned in Israel via its agreements with three farms with cultivation licenses. These operations have a fully-funded capacity of 232,900 sq. ft. with the ability to produce 23,500 kilograms of cannabis per year. Management believes these operations can be further scaled to produce 50,000 kilograms per year with a low production cost of just 40 cents per gram given the unique climate and technologies.
What’s Next for Israel’s Cannabis Market?
It is anticipated that new guidelines will enable more patients to purchase cannabis at pharmacies with a prescription. Currently, the law is restricted to patients suffering from Parkinson’s, epilepsy, cancer, and other terminal illnesses, which has limited demand. The new law is expected to go into effect imminently.
Over the longer-term, Israel appears to be moving closer to a fully-legalized cannabis market. Mainstream political parties have been supportive of cannabis legalization and there’s widespread demand from the public for reforms. Decriminalization and wider medical cannabis use are a great first step, but the country’s cannabis market won’t realize its true potential until adult-use cannabis is legalized and export laws go into effect. Fortunately, Israel legalized exports in January 2019, initiating a massive catalyst for the Israeli market.
ISRACANN Biosciences Inc. [Canadian Listed: IPOT (Pending)] plans to become fully operational in the near-term with initial harvests expected by the first quarter of 2020. Given the strong valuations across North American cannabis companies, investors may want to keep a close eye on the stock ahead of its listing on a Canadian Stock Exchange later this year. The unique exposure to Israel’s market and the potential to expand into Europe are key catalysts.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.